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Review articles
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For the last four years Greece has faced a large number of infections, 
mainly in the intensive care units (ICU), due to carbapenem-
resistant, VIM-1-producing Klebsiella pneumoniae. The proportion 
of imipenem-resistant K. pneumoniae has increased from less 
than 1% in 2001, to 20% in isolates from hospital wards and 
to 50% in isolates from ICUs in 2006. Likewise, in 2002, these 
strains were identified in only three hospitals, whereas now they 
are isolated in at least 25 of the 40 hospitals participating in 
the Greek Surveillance System. This situation seems to be due to 
the spread of the blaVIM-1 cassette among the rapidly evolving 
multiresistant plasmids and multiresistant or even panresistant 
strains of mainly K. pneumoniae and also other enterobacterial 
species. However, the exact biological basis of this phenomenon 
and the risk factors that facilitate it are not yet fully understood. 
Moreover, the fact that most strains display minimum inhibitory 
concentration (MIC) values below or near the Clinical Laboratory 
Standard Institute (CLSI) resistance breakpoint create diagnostic 
and therapeutic problems, and possibly obstruct the assessment 
of the real incidence of these strains. 
An evidence-based consensus on the therapeutic strategy for these 
infections is urgently needed. The problem of VIM-producing K. 
pneumoniae was timely recognized by the Greek System for the 
Surveillance of Antimicrobial Resistance and various guidelines, 
including  advice  on  antibiotic  policy  and  infection  control, 
were developed by the National Centre for Disease Control and 
Prevention. However, these measures have yet had a relatively small 
impact on the situation. The best way to handle the problem of 
antibiotic resistance would be the development and implementation 
of a national integrated strategic action plan (currently under 
development) affirming the political commitment of the public 
health administration in confronting this issue. 
Introduction 
Resistance to carbapenem due to the production of metallo-
beta-lactamases (MBL) in Gram-negative organisms is an increasing 
international public health problem [1,2]. The problem of MBL-
producing strains in Europe was originally confined to Pseudomonas 
aeruginosa. P. aeruginosa harbouring MBL of the VIM-1 type were 
first isolated in 1997 in Italy [3] and France [4]. 
In Greece the first outbreak of P. aeruginosa harbouring MBL 
occurred in a hospital in Thessaloniki in 1996, and was reported 
in 2000 [5]. This enzyme was soon identified as VIM-2, an enzyme 
similar but not identical to VIM-1 [6]. By 2001, a multicentre study 
revealed that VIM-2-producing P. aeruginosa had already been 
isolated in nine out of 18 hospitals examined [7]. 
In the above context, the isolation of VIM-producing enteric 
bacteria (mainly K. pneumoniae, but also Escherichia coli, Proteus 
mirabilis, Enterobacter spp and other) in Greece since November 
2001 seems to be an important new chapter in the epidemiology 
of this resistance mechanism. 
It must be noted that sporadic isolates and small outbreaks 
of VIM-producing enteric bacteria have been reported in some 
European and Mediterranean countries [8-11], with the strains 
being traced back to Greece on some occasions [12]. However, 
Greece seems to be the only country where these clinical strains 
are isolated in high numbers (Figure 1). This constitutes a major 
public health problem for Greece and also a possible threat for the 
rest of Europe. 
The purpose of this report is to review the current knowledge 
concerning the epidemiology, microbiology, molecular biology, 
Figure 1
Proportion of carbapenem-resistant Klebsiella pneumoniae 
isolates in EARSS participating countries, 2006. 
Data from European Antimicrobial Resistance Surveillance System (EARSS), http://
www.rivm.nl/earss/database/
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clinical management as well as the public health issues related 
to this problem. 
The review is mainly based on reports published by all scientific 
groups working in the area of antibiotic resistance in Greece. These 
papers were retrieved by a systematic Medline search. 
In addition, data concerning the magnitude and the development 
of the problem of VIM-producing enteric bacteria were derived 
from the Greek System for the Surveillance of Antimicrobial 
Resistance (GSSAR, http://www.mednet.gr/whonet) which has 
been in operation since 1996, and currently involves 40 hospitals 
around Greece. GSSAR participates in the European Antimicrobial 
Resistance Surveillance System (EARSS) and is in charge of the 
continuous analysis of the routine data generated in the hospital 
microbiology laboratories with the aid of the WHONET software. A 
brief description of the system can be found elsewhere [13]. 
Description of the situation 
The first VIM-producing enteric bacterium in Greece was an E. 
coli isolated in November 2001, and reported early in 2003, in a 
hospital in Piraeus [14]. Since then VIM-producing E. coli have 
been reported sporadically [15,16], and hospital outbreaks have 
also occurred [17]. 
VIM-producing K. pneumoniae were first reported between 
September and December 2002 in the intensive care units (ICUs) 
of three teaching hospitals located in Athens [18]. The exact origin 
of the index case was not revealed. 
An outbreak of MBL-producing P. mirabilis was described in a 
general hospital in Thessaloniki during the period from June 2004 
to March 2005 [19], as well as in outpatients believed to have been 
related to a general hospital in Sheres, in Northern Greece [20]. 
Finally MBL production was also sporadically described in 
Enterobacter cloacae in 2003 [21], in Enterobacter aerogenes in 
2004 [15], in Morganella morganii in 2005 [22] and in Providencia 
stuartii in 2007 [23]. 
Concerning the magnitude of the problem, the GSSAR data 
reveal a steep increase in the proportion of imipenem-resistant K. 
pneumoniae from less than 1% in 2001 to 20% in isolates from 
hospital wards and to 50% in isolates from ICUs in 2006 (Figure 
2). Accordingly, these resistant strains were identified in only three 
hospitals in 2002, and now are isolated in at least 25 of the 40 
hospitals participating in the GSSAR network (Figure 2). 
Interestingly, the proportions of imipenem-resistant enteric 
bacteria other than K. pneumoniae continue to be low (http://
www.mednet.gr/whonet). 
At this point it should be underlined that these data have to 
be interpreted with caution since resistance to carbapenem is 
monitored by the GSSAR network through the analysis of sensitivity 
data and not through the detection of the blaVIM gene (see next 
section). 
Very little work has been done concerning the identification of risk 
factors for carbapenem-resistant infections. Fluoroquinolone and 
antipseudomonal penicillins have been proposed as independent 
risk factors in one matched case-control study [24]. 
Related clinical microbiology issues 
Although the first VIM-producing K. pneumoniae and E. coli 
isolates were initially recognised by their in vitro resistance to 
carbapenem, i.e. displaying minimum inhibitory concentration 
(MIC) falling at the Clinical Laboratory Standard Institute (CLSI) 
resistant category in the in vitro sensitivity testing, it was soon 
documented that quite a few strains expressed low levels of 
resistance to carbapenem with MIC values at the CLSI intermediate 
resistance category (MIC 8 mg/L) or even at the sensitive category 
but with values near the breakpoint (MIC 2-4 mg/L). However, 
it must be emphasized that a strong inoculum effect has been 
reported – increasing the cell density by 102 CFU/mL raised 
carbapenem MICs by 2-6 doubling dilutions. This inoculum effect 
was more pronounced with imipenem [25]. 
The behaviour of these strains in the various automatic sensitivity 
testing systems was also studied quite early, and discrepancies 
were reported [26]. Moreover, due to inadequate scaling, the MBL-
detecting Etest strips containing imipenem plus EDTA produced 
a synergy image between imipenem and EDTA, occurring as a 
“phantom zone”, and making the interpretation of the result 
difficult. 
On the contrary, the fact that Proteus spp, displaying intrinsically 
high MICs to imipenem in the wild type population (see wild-
type distributions published by EUCAST at: http://www.srga.org/
eucastwt/MICTAB/index.html), has resulted in many false positive 
reports of imipenem-resistant Proteus, mainly in laboratories that 
use automatic susceptibility testing methods. 
All these characteristics hamper the detection of the VIM-
producing strains, pose therapeutic questions and obstruct the 
assessment of the real incidence of these strains, due to a possible 
iceberg phenomenon created by the presence of the in vitro 
“sensitive” strains harbouring the blaVIM gene. 
Consequently, it was soon recognised that a special phenotypic 
test for the detection of these strains should be adopted. The 
double-disk imipenem – EDTA synergy test already in use for the 
detection of MBL-producing P. aeruginosa [2,7] was suggested for 
the identification of MBL production in all enteric bacteria isolates 
with an MIC to imipenem >=1 mg/ml [27]. However, this problem 
Figure 2
Trends in proportion of imipenem-resistant Klebsiella 
pneumoniae isolates in hospitals in Greece, 2000-2006
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has not been studied further and official recommendations have 
not been issued yet. 
The  diversity  of  carbapenem  resistance  levels  in  the  K. 
pneumoniae carrying blaVIM-1 gene was associated in one study 
[28] either with multiple copies of the gene on the plasmid 
backbone – a procedure generated by IS26 activity – or due to porin 
loss – a fact indicating that the clinical use of carbapenem and, to 
a lesser extent, cefepime and aztreonam, against the phenotypically 
susceptible isolates of this group may have possibly contributed to 
the selection of the high-level resistance isolates. 
Related molecular epidemiology issues  
Genes 
The spread of MBL-producing enteric bacteria in Greece is 
generally found to be due to VIM-1 type genes in the form of gene 
cassette [14,16-19,21,22] which are genetically different to the 
VIM-2 type genes isolated in P. aeruginosa in this country [6,7]. 
Interestingly, the blaVIM-1 cassette (including the 81 nucleotides 
of the 59-base element) was found identical to that originally 
described in P. aeruginosa in Italy and other European countries 
[14,18,21]. 
A different blaVIM gene termed blaVIM-12 was isolated in one 
Klebsiella pneumoniae and one E. coli isolate. This gene could be 
viewed as a blaVIM-1/blaVIM-2 hybrid being identical to blaVIM-1 
from the 5_ end up to nucleotide 663, and to blaVIM-2 from 
nucleotide 614 up to its 3_ end [29,30]. Furthermore, the 59-base 
element of the blaVIM-12 gene cassette (72 bp in length) was 
identical to the element commonly found in blaVIM-2 cassettes 
and differed significantly from the 59 bp of the blaVIM-1 gene 
cassettes [29,30]. 
Integrons 
The VIM gene was generally found to be part of related type I 
integrons. The cassette region of these integrons typically contains 
(from 5_ to 3_) the blaVIM-1, and the aacA4, dhfrI, and aadA 
genes [14,18,19]. 
However, a type I integron carrying the blaVIM-1 gene and a 
6_-N-aminoglycoside acetyltransferase (aac(6_)-Ib) gene cassette 
was described in an E. cloacae clinical isolate [21]. Moreover, a 
different integron structure suggesting a different evolution process 
rather than a transfer, and the spread of the mobile element among 
the Greek hospitals was described in a cluster of four E. coli isolates 
in Crete [17]. 
Similarly, a novel class 1 integron carrying a carbapenemase gene 
(blaVIM-1) associated with a trimethoprim (dfrA1), a streptothricin 
(sat1) and two aminoglycoside resistance genes (aacA7 and aadA1) 
was detected in a Morganella morganii clinical isolate [22]. 
Moreover, a class I integron carrying only the blaVIM-1, and the 
dhfrI and aadA genes was found in a plasmid isolated from three 
different bacterial genera [15]. Lastly, an integron solely carrying 
the blaVIM-1 gene was described in an E. coli isolate [16]. 
Integrons are not self-transferred elements, and are commonly 
associated with various transposons. An IS26 insertion into the 
5_ conserved segment of an In4-type integron and an IS26-
mediated recruitment of resistance genes of diverse origin have 
been suggested as a mechanism for the evolution of various 
multiresistant integrons, including those that harbour the blaVIM-1 
genes [31]. However, further work on the exact mechanism of their 
development and dissemination is needed. 
The coexistence of the blaVIM gene with various other, newer 
beta-lactamases, including SHV-5 [18], the IBC-1 [32], the GES7 
[16] the CMY-4 [33] and the CTX-M [17] genes have also been 
reported. 
Plasmids 
The  blaVIM  containing  integrons  are  mainly  found  to  be 
harboured by transferable plasmids in most enteric bacteria species 
including K. pneumoniae [18], E. coli [14,17], P. mirabilis [15], 
Enterobacter aerogenes [15] and Providencia stuartii [23]. 
Interestingly, the chromosomal location of the VIM containing 
integrons was also documented on several occasions, including an 
epidemic clone of P. mirabilis in Thessaloniki [19], and sporadic 
E. coli [16], Enterobacter cloaca [21] and Morganella morganii 
[22] isolates. 
The epidemiology of the blaVIM harbouring plasmids is an 
important prerequisite for understanding the dynamics of the 
growing proportion of VIM-producing strains. These plasmids 
were generally found to display different restriction patterns [18], 
although the spread of plasmids with identical patterns in isolates 
of the same species [17,18], or even among isolates of different 
species [15] has also been described. Most importantly, in at least 
one study, plasmids harbouring the blaVIM-1 gene were found to 
belong to the incompatibility group N [34], a fact consistent with 
the possible spread of evolving plasmids. However, these issues 
must be further elucidated. Plasmids of other than N incompatibility 
groups have also been sporadically isolated [33]. 
Bacterial strains 
Another important condition for understanding the situation 
is the study of the possible clonal spread of the VIM-producing 
strains. Although much work needs to be done on this issue, the 
epidemics seem to be generally multiclonal, with clones differing 
between hospitals and sometimes even different clones present 
within a single hospital [18], with no particular clone prevailing 
(unpublished data from our department). A few exceptions to this 
rule have been reported: an outbreak in distinct regions of Greece 
due to a single K. pneumoniae clone carrying a blaVIM-1 gene [35], 
a small nosocomial outbreak due to a VIM-producing E. coli clone 
[17], and one caused by a VIM-producing P. mirabilis clone [19]. 
A recently published study on blood isolates from three hospitals 
in Athens revealed that 37.6% of all K. pneumoniae blood isolates 
were blaVIM-1-positive. 77.8% of these were taken from ICUs. 
PFGE identified eight clusters (A-H) with related (>80%) patterns, 
as well as four unique types. Microorganisms producing both VIM-1 
and SHV-5 constitute the prevalent multidrug-resistant population 
of K. pneumoniae in this setting [36]. 
In conclusion, the large and still increasing proportion of 
VIM-producing K. pneumoniae seems to be due to the spread 
of the blaVIM-1 cassette among rapidly evolving multiresistant 
plasmids and multiresistant or even panresistant strains mainly of 
K. pneumoniae but also, of other enteric bacteria species. However, 
further work is needed to elucidate the possible contribution of 
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Related clinical issues 
Imipenem-resistant isolates are generally found to be multidrug-
resistant,  the  majority  displaying  resistance  to  at  least  one 
aminoglycoside, quinolones and trimpethoprim [37, unpublished 
data from the GSSAR]. Interestingly, most isolates were found to 
be resistant to aztreonam, indicating the simultaneous presence of 
other extended-spectrum beta-lactamases (ESBL) as well [37]. 
The multidrug-resistant nature of these isolates dramatically 
limits the therapeutic options, leaving colistin, a toxic and difficult-
to-use drug, as the only antibiotic with in vitro activity against VIM-
producing enteric bacteria. However, VIM-producing K. pneumoniae 
displaying resistance to colistin, with an MIC up to 64 mg/L have 
sporadically being isolated [unpublished data from the GSSAR], 
and at least one outbreak has been described [38]. 
Taking this into account, and given the in vitro low levels of 
resistance displayed by most isolates, the question of the possible 
treatment of these patients with high levels of carbapenem has so 
far been addressed by two published reports. 
The in vivo activity of imipenem against VIM-producing K. 
pneumoniae was assessed in a thigh infection model in neutropenic 
mice by Daikos et al. [39]. The authors concluded that while their 
results cannot provide firm conclusions regarding the treatment of 
infections caused by VIM-producing K. pneumoniae strains with 
MIC of imipenem in the susceptible range, they suggest that the 
administration of imipenem at higher doses may prove to be of 
some benefit. 
Moreover, a retrospective analysis of 28 cases of VIM-producing 
K. pneumoniae bloodstream infections [40] revealed a striking 
difference in mortality between patients infected with VIM-producing 
K. pneumoniae with MIC of imipenem >4 g/mL and control group 
patients infected with non-VIM-producing K. pneumoniae. In 
contrast, patients infected with VIM-producing K. pneumoniae 
but with MIC of carbapenems in the susceptible range displayed 
no difference in mortality compared to the control group. 
In addition to these studies, Galani et al. have reported both 
successful [15] and non-successful [21] outcomes of patients 
infected with low-level-resistant VIM-producing enteric bacteria 
and treated with imipenem. 
However, all these reports must be regarded as preliminary, and 
well designed prospective studies are urgently needed to tackle 
the therapeutic issues set by VIM-producing K. pneumoniae, as 
well as the possible need to modify the clinical breakpoints to 
carbapenems for the blaVIM harbouring strains. 
Related public health issues 
It is well recognized that the main tools for confronting antibiotic 
resistance are antibiotic policy and infection control strategies 
[41]. 
The problem of VIM-producing K. pneumoniae was timely 
recognized by the GSSAR, and its significance adequately assessed 
and publicized by the Infectious Disease and Clinical Microbiology 
community in Greece. Moreover, the National Early Warning System 
for the Recognition of New and Emerging Resistance Mechanisms, 
which has been in operation in Greece for the last two years, was 
successfully used for the early tracing and reporting of VIM-
producing enteric bacteria. Additionally, the National Centre for 
Disease Control and Prevention at the Greek Ministry of Health 
(KEELPNO) issued guidelines which were distributed to the 
hospitals as soon as a VIM-producing strain had been isolated 
there. These guidelines were mainly addressed to the “Infection 
Control Committee” of the respective hospitals and included issues 
on antibiotic policy and infection control. 
To date, however, these measures have made a relatively 
small impact on the still increasing proportion of VIM-producing 
strains. 
It is well accepted that antibiotic resistance is a difficult-to-
manage public health problem, especially when it is established. 
This is particularly true in the case of the complex molecular 
epidemiology of the VIM-producing K. pneumoniae problem in 
Greece. 
Furthermore, Greece is among the countries which for decades 
have been reporting the highest levels of resistance to most 
antibiotics [42,43] and therefore physicians may not always 
recognize  the  possible  significance  of  a  new  mechanism  of 
resistance. 
Antibiotics are the most important risk factors in the development 
of resistance, and therefore an effective antibiotic policy, in addition 
to being an important element of good medical practice, is an 
important public health measure in confronting the problem of 
antimicrobial resistance [44,45]. Especially since Greece is among 
the European countries with the highest rates of antibiotic use in 
both hospital and community settings [46,47]. 
It must be emphasized, however, that for the antibiotic policy 
to be effective, it must be based on a good understanding of the 
molecular basis of the resistance mechanisms [48]. Moreover, in 
an area such as Greece, with high resistance rates and very few 
effective antibiotics left at the physician’s disposal, antibiotic policy 
has very narrow limits. What is more, antibiotic policy must always 
be combined with infection control. 
In addition to the above difficulties, certain characteristics 
of the public health system in Greece, especially the fact that 
public health is relatively undersized within the national health 
system, hinders the effort to confront antibiotic resistance. The 
hospital epidemiologist is not a recognized specialist in Greece 
and hospital epidemiology is not part of the everyday practice 
in Greek hospitals. Although there is expertise available in many 
hospitals and university laboratories, the strains isolated from 
cases of healthcare-associated infections are not routinely typed. 
Hospital outbreaks are not routinely studied and the possible role 
of the spread of drug-resistant clones in these outbreaks is not 
routinely assessed. The “Infection Control Committees” in hospitals 
do not have administrative authority, infection control measures 
are not always implemented in practice, while infectious diseases 
specialists, with no official training in epidemiology, are mainly 
focused on antibiotic policy [49,50]. 
In summary, a national Strategic Action Plan is a necessary 
public health instrument to coordinate efforts, prioritize activities, 
set goals and audit actions, and thus to answer all important 
issues related to the spread of drug-resistant enteric bacteria 
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under development and hopefully will be available in the next few 
months. The plan will affirm the political commitment of the Greek 
health administration in confronting the issue of antimicrobial 
resistance. It will put emphasis on this public health problem and 
its risk factors in a way to be understood by the wider medical 
community, the health policymakers and the wider community. It 
will allocate specific tasks to the responsible bodies and coordinate 
and prioritize the necessary scientific research. The Action Plan 
will be based on the collaboration, coordination and consensus of 
opinions of all parties involved.
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